Roche silences Herceptin comparison

Share this article:

Biosimilar Herceptin is coming to India, but marketers will not be able to say so. The Wall Street Journal reported Friday that drugmaker Roche won a case that prevents the biosimilar manufacturer from using the brand name Herceptin in its marketing.

The decision also bars Biocon-Mylan from making comparisons between its lookalike breast cancer treatment's manufacturing processes, safety, efficacy and sales, with those of Herceptin.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.